Nano-Photosensitizer Directed Targeted Phototherapy Effective Against Oral Cancer in Animal Model
Lina Yu,Guanxiong Zhu,Zeyu Zhang,Zidan Xu,Weijie Peng,Liting Zeng,Yang Yu,Siran Wang,Zhongxiao Lin,Xin Zhang,Na Zhou,Lingmin Zhang,Lu Liang
DOI: https://doi.org/10.2147/ijn.s434917
IF: 7.033
2023-11-02
International Journal of Nanomedicine
Abstract:Lina Yu, 1, &ast Guanxiong Zhu, 1, &ast Zeyu Zhang, 1, &ast Zidan Xu, 1 Weijie Peng, 1, 2 Liting Zeng, 1 Yang Yu, 3 Siran Wang, 1 Zhongxiao Lin, 1, 2, 4 Xin Zhang, 4 Na Zhou, 4 Lingmin Zhang, 1, 2 Lu Liang 1, 2 1 Department of Preventive Dentistry, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Guangzhou, 510182, People's Republic of China; 2 Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China; 3 Department of Sports and Health, Guangzhou Sport University, Guangzhou, People's Republic of China; 4 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wailong, Taipa, Macau, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lingmin Zhang; Lu Liang, Email ; Background: Photodynamic therapy (PDT) has emerged as a promising strategy for oral cancer treatment. Verteporfin is a powerful photosensitizer and widely used in the treatment of macular degeneration. However, rare work has reported its potential in the treatment of oral cancer. Methods: In this study, we introduce an innovative approach of nano-photosensitizer based on Verteporfin, which was prepared by utilizing macrophage membrane to coat Verteporfin-loaded zeolitic imidazolate framework 8 (ZIF-8) for effective photodynamic therapy against oral cancer. Nanoparticle characteristics were assessed including size, zeta potential, and PDI. Cellular uptake studies were conducted using CAL-27 cells. Furthermore, inhibitory effects in both in vitro and in vivo settings were observed, ensuring biosafety. Assessment of anticancer efficacy involved tumor volume measurement, histological analyses, and immunohistochemical staining. Results: In vitro experiments indicated that the nano-photosensitizer showed efficient cellular uptake in the oral cancer cells. Upon the laser irradiation, the nano-photosensitizer induced the generation of reactive oxygen species (ROS), leading to cancer cell apoptosis. The in vivo experiments indicated that the coating with cell membranes enhanced the circulation time of nano-photosensitizer. Moreover, the specificity of the nano-photosensitizer to the cancer cells was also improved by the cell membrane-camouflaged structure in the tumor-bearing mouse model, which inhibited the tumor growth significantly by the photodynamic effect in the presence of laser irradiation. Conclusion: Overall, our findings demonstrate the potential of macrophage membrane-coated ZIF-8-based nanoparticles loaded with Verteporfin for effective photodynamic therapy in oral cancer treatment. This nano-system holds promise for synergistic cancer therapy by combining the cytotoxic effects of PDT with the activation of the immune system, providing a novel therapeutic strategy for combating cancer. Keywords: photodynamic therapy, verteporfin, oral cancer, macrophages, zeolitic imidazolate framework 8 Tongue squamous cell carcinoma (TSCC) is a prevalent and highly fatal form of oral cancer. 1 This cancer type is marked by a grim prognosis, frequent lymphatic metastasis (spread to nearby lymph nodes), and a notable rate of regional recurrence. The conventional treatment protocol for TSCC entails surgery, followed by postoperative radiotherapy and chemotherapy. Nonetheless, despite these treatments, the 5-year overall survival rate for TSCC has not exhibited significant enhancement in recent years. 2 Therefore, it is imperative to formulate precise and personalized treatment strategies. Verteporfin, marketed as Visudyne and approved by the FDA, is primarily employed for the treatment of specific severe eye conditions, notably age-related macular degeneration (AMD). Beyond its ophthalmic use, preclinical investigations have unveiled the potential utility of verteporfin in cancer therapy, encompassing liver, pancreatic, gastric, and head and neck cancers. 3–7 In the realm of cancer research, Verteporfin is under scrutiny as a photosensitizer for photodynamic therapy, holding promise as a modality for cancer treatment. In this approach, the drug is -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology